Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Diabetes and chronic kidney disease (CKD) are two of the most common chronic illnesses in the world. Both can have serious consequences if left untreated, but proper management can help reduce the risk of further complications. This article will provide an overview of diabetes and CKD, discuss risk factors for …
Read More »Young Age at diabetes diagnosis amplifies the effect of diabetes duration on risk of chronic kidney disease
Young age at diagnosis or disease aggression which increases lifetime risk of CKD in type 2 patients with diabetes Type 2 Diabetes, once considered a disease that comes about at an older age, is now increasingly diagnosed in younger adults. The number of people between the ages of 20-39 years …
Read More »The Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone: A New Option for Patients with Diabetic Kidney Disease
Allison S. Rembert, PharmD Candidate 2024 Adrian K. Baker, PharmD Candidate 2024 Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Department of Pharmacotherapy College of Pharmacy and Pharmaceutical Sciences Washington State University A 55-year-old female with type 2 diabetes (T2D) and chronic kidney disease (CKD) presented to the ambulatory care clinic. …
Read More »GLP-1 vs. DPP-4 in Reducing Mortality for T2D Patients with ESRD
Glucagon-like peptide-1 (GLP-1) receptor agonist can reduce mortality and improve cardiovascular outcomes among patients with type 2 diabetes and end-stage kidney disease, compared to dipeptidyl peptidase -4 inhibitor use.
Read More »Can a Calorie-Restricted Diet Improve Long-Term Progressive Kidney Function Decline?
Studies have found that there may be a benefit in implementing a calorie-restricted diet in patients with type 2 diabetes to improve glomerular hyperfiltration.
Read More »Dapagliflozin is a Potential Treatment Option for Chronic Kidney Disease Patients
DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status.
Read More »The Benefit of Intensive Albuminuria Lowering In Patients With Type 2 Diabetes
Hyperuricemia has been implicated in the development and progression of chronic kidney disease, and the effects of intensive albuminuria lowering may be beneficial.
Read More »Finerenone Use In Patients With CKD and Type 2 Diabetes
According to research presented by Dr. George Bakris of the University of Chicago, treatment with finerenone resulted in a lower risk of the progression of chronic kidney disease and cardiovascular events.
Read More »Dapagliflozin Gets Nod as a Breakthrough Therapy Designation for CKD
Dapagliflozin (Farxiga®) has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) for patients with chronic kidney disease (CKD), whether or not they have type 2 diabetes.
Read More »Evaluation of CVD/CKD Risks in Patients with Type 2 Diabetes
Despite being on first-line oral anti-diabetic drug therapy, the risk of developing CVD/CKD in patients with type 2 diabetes remains high.
Read More »